Valuation: Revance Therapeutics, Inc.

Market Cap 319M 273M 255M 234M 439M 30.51B 448M 3.02B 1.18B 15.29B 1.2B 1.17B 50.63B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 465M 434M 398M 749M 52B 763M 5.15B 2.01B 26.06B 2.04B 2B 86.27B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
19.01
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap.
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-78.91% 383M
-1.69%+2.56%+39.87%+1.75% 82.54B
-23.55%+109.46%+395.80%+31.19% 53.23B
-1.69%+23.30%-25.53%-36.93% 58.38B
+1.94%+0.64%+0.46%+32.78% 52.24B
-0.46%+2.17%+8.99%+166.13% 48.52B
-3.25%+1.76%+54.22%-17.92% 31.67B
-0.97%+5.56%+47.59%+98.66% 25.79B
+1.19%+9.17%+3.12%+228.73% 22.46B
-0.35%+4.13%+60.35%+123.49% 16.91B
Average -0.33%+15.31%+58.49%+54.90% 39.21B
Weighted average by Cap. -0.45%+20.06%+69.78%+47.42%

Financials

2022 2023
Net sales 133M 114M 106M 97.17M 183M 12.68B 186M 1.26B 490M 6.36B 498M 487M 21.05B 234M 200M 187M 172M 322M 22.39B 329M 2.22B 865M 11.22B 879M 860M 37.16B
Net income -356M -305M -285M -261M -491M -34.1B -501M -3.38B -1.32B -17.09B -1.34B -1.31B -56.58B -324M -277M -259M -237M -446M -31B -455M -3.07B -1.2B -15.54B -1.22B -1.19B -51.44B
Net Debt 77.76M 66.58M 62.12M 57M 107M 7.44B 109M 737M 287M 3.73B 292M 286M 12.35B 225M 192M 179M 165M 309M 21.48B 315M 2.13B 829M 10.77B 843M 825M 35.64B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock